Ready, Set, Goal: Motivation and Cognition in Stroke Patients (ACE)

October 25, 2019 updated by: Dr. Richard H. Swartz, Sunnybrook Health Sciences Centre

Ready Set Goal: A Randomized Controlled Trial Examining Motivation and Cognition in Stroke Patients

Apathy is a syndrome of reduced motivation, characterized by diminished goal-directed behaviours (e.g., lack of effort), decreased goal-oriented cognitions (e.g., lack of interest) and blunted affect. Apathy is present in 20-50% of individuals after experiencing a stroke. Despite the detrimental impact of reduced goal-directed behaviours and cognitions on activities of daily living and cognition in stroke patients, interventions for increasing motivation (reducing apathy) have yet to be examined in this population. This study will examine the effect of goal-setting instructions on cognitive performance in stroke patients. The investigators hypothesize that in stroke patients, goal-setting instructions will improve cognitive performance relative to standard instructions. If goal-setting instructions are effective in improving cognitive performance, it may indicate that treatments targeting apathy could serve as a novel way to improve cognitive outcomes and enhance patient quality of life post-stroke.

Study Overview

Detailed Description

The study is a single-blind randomized controlled trial. It employs a mixed design, with a between-subjects variable (goal-setting instructions versus standardized instructions) and a within-subjects variable (pre-post instructional manipulation). It is a one-time intervention lasting 1-2 hours. Investigators plan to enroll 72 patients in this study. All participants will complete neuropsychological measures to assess their baseline performance. The baseline measures include Trial 1 of the CVLT-II Alternate Form, the Digit Span Test, Center for Epidemiologic Studies Depression Scale, Controlled Oral Word Association Test, Semantic Fluency Test, Apathy Evaluation Scale and Trail Making Test. After the baseline measures are completed, all participants will rate their level of motivation on a scale from 1 (extremely unmotivated) to 100 (extremely motivated), which will act as a pre-manipulation check measure, their level of fatigue on a scale from 1 (extremely not fatigued) to 100 (extremely fatigued), and their level of anxiety from 1 (extremely not anxious) to 100 (extremely anxious; 1 minute).

After completing the baseline measures and rating scales, half (n = 36) of the participants will be randomly assigned to the goal-setting instruction group ("goal-setting group"). Motivation will be enhanced by asking participants to perform 20% better than their previous performance on a similar task, and translating that into a number (e.g., "On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter "F." Now, for the next letter, I want you to generate 12 words."). The remainder of the participants (n = 36) will be assigned to the "standard instruction group," where they will only receive the standardized instructions for completing the tests.

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Health Sciences Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient attending Secondary Stroke Prevention Clinic
  • Ischemic Stroke
  • Presenting at least 3 months after stroke
  • Modified Rankin Scale Score of at least 4
  • Fluent in English

Exclusion Criteria:

  • Marked aphasia
  • Marked neglect
  • Severe visual impairment
  • Inability to complete 1 hour of cognitive testing in English.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Standard Instructions
Participants will receive standard instructions for cognitive tasks.
Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
Experimental: Goal Setting Instructions
Participants will receive goal-setting instructions for cognitive tasks.
Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., "On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.")

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Controlled Oral Word Association Task
Time Frame: 10 minutes
Participant performance on Controlled Oral Word Association Task in goal setting instructions group compared to standard instruction group.
10 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Motivation Level
Time Frame: 2 minutes
Participant self-reported motivation level in goal setting instruction group versus standard instruction group.
2 minutes
Cognitive Performance on Semantic Fluency Test
Time Frame: 10 minutes
Participant performance on Semantic Fluency Test in goal setting instructions group compared to standard instruction group.
10 minutes
Digit Span Test
Time Frame: 10 minutes
Participant performance on Digit Span Test in goal setting instructions group compared to standard instruction group.
10 minutes
California Verbal Learning Test-II
Time Frame: 10 minutes
Participant performance on California Verbal Learning Test-II in goal setting instructions group compared to standard instruction group.
10 minutes
Trail Making Test
Time Frame: 10 minutes
Participant performance on Trail Making Test in goal setting instructions group compared to standard instruction group.
10 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Director: Keera Fishman, B.Sc, Sunnybrook Health Sciences Centre/ University of Ottawa

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2018

Primary Completion (Actual)

October 1, 2019

Study Completion (Actual)

October 25, 2019

Study Registration Dates

First Submitted

February 12, 2018

First Submitted That Met QC Criteria

April 17, 2018

First Posted (Actual)

April 27, 2018

Study Record Updates

Last Update Posted (Actual)

October 29, 2019

Last Update Submitted That Met QC Criteria

October 25, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plan to make IPD available.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe